A total of 566 patients in the NORDIC VII Study were randomized 111 to arm A ( Nordic FLOX ) , arm B ( Nordic FLOX + cetuximab ) , or arm C ( Nordic FLOX + cetuximab for 16 weeks followed by cetuximab alone as maintenance therapy ) .